Want to join the conversation?
R&D focused biotechnology company $ENTA said that the FDA has approved AbbVie's supplemental New Drug Application (sNDA) for the use of VIEKIRA PAK without ribavirin (RBV) in patients with genotype 1b (GT1b) chronic hepatitis C virus infection and compensated cirrhosis, a liver-related disease.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.